(What will be mentioned in this article is for advice and is not a substitute for consulting a doctor)
Awiqli FDA Approval 2026: First Once-Weekly Insulin for Type 2 Diabetes Marks a Major Breakthrough in Diabetes Care
Diabetes Dialogue: FDA Approves Novo Nordisk’s Insulin Icodec-abae (Awiqli) for T2D - HCPLive
Key Points
The U.S. FDA approved Awiqli® (insulin icodec-abae) on March 26, 2026.
Awiqli is the first and only once-weekly basal insulin approved in the United States for adults with Type 2 Diabetes.
Developed by Novo Nordisk, the treatment reduces basal insulin injections from 365 per year to approximately 52 per year.
Approval was supported by the large global ONWARDS Phase 3a clinical trial program involving about 2,680 adults with uncontrolled Type 2 Diabetes.
Clinical studies showed significant reductions in HbA1c (A1C) and blood glucose levels compared with daily basal insulin therapies.
Recent medical publications and expert reviews released during April and May 2026 continue to highlight Awiqli as one of the most important diabetes treatment advances in more than two decades.
The FDA approval currently applies only to adults with Type 2 Diabetes; approval for Type 1 Diabetes remains unresolved because of hypoglycemia concerns identified in previous regulatory reviews.
advertisement
A major milestone in diabetes treatment arrived in 2026 when the U.S. Food and Drug Administration (FDA) approved Awiqli® (insulin icodec-abae), making it the first-ever once-weekly basal insulin available for adults living with Type 2 Diabetes in the United States. The approval, announced by Novo Nordisk in late March 2026, represents one of the most significant innovations in insulin therapy in more than twenty years and could dramatically change how millions of people manage their diabetes.
Unlike traditional long-acting insulin products that require daily injections, Awiqli is administered only once every seven days, offering a simpler treatment schedule while maintaining stable blood sugar control throughout the week. Healthcare experts believe this approach may help improve medication adherence because many patients struggle to consistently take daily insulin injections. Reducing the treatment burden from seven injections per week to one could potentially improve long-term diabetes management and quality of life for many patients.
The FDA approval was based on results from the extensive ONWARDS Phase 3a clinical development program, which enrolled approximately 2,680 adults with uncontrolled Type 2 Diabetes across multiple randomized, active-controlled studies. Researchers compared once-weekly insulin icodec with widely used daily basal insulin treatments such as insulin degludec and insulin glargine. Across these trials, participants receiving Awiqli achieved meaningful reductions in HbA1c (A1C) levels, a key measure of long-term blood sugar control. The studies demonstrated that the weekly insulin met primary efficacy goals while maintaining a safety profile generally consistent with the basal insulin class.
Recent medical reviews and expert analyses published during April and May 2026 have continued to spotlight Awiqli's approval as a landmark event in endocrinology and diabetes care. Experts writing in medical journals noted that insulin icodec introduces a completely new dosing paradigm for basal insulin treatment, potentially reducing injection fatigue and improving patient convenience. Several analyses also emphasized that the approval represents the first new basal insulin category introduced to U.S. patients in more than two decades.
Awiqli is approved as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 Diabetes and may be used alongside oral diabetes medications, GLP-1 receptor agonists, and mealtime insulin when clinically appropriate. The medication is supplied as a 700 units/mL injection in a prefilled FlexTouch pen, specifically designed for weekly administration. Patients are generally instructed to administer the injection on the same day each week to maintain consistent insulin coverage.
While the Type 2 Diabetes approval marks a major success, the regulatory path for Type 1 Diabetes remains more complex. Previous FDA advisory committee reviews highlighted concerns about increased risks of severe or clinically significant hypoglycemia in Type 1 Diabetes patients using insulin icodec. Because of these findings, the current U.S. approval is limited to adults with Type 2 Diabetes. Researchers continue to evaluate strategies that may improve safety and optimize dosing in other patient populations.
Industry analysts expect Awiqli to play an important role in the evolving diabetes treatment market, where healthcare providers increasingly seek therapies that combine strong glucose control with greater convenience. The approval also intensifies competition in the emerging once-weekly insulin category, with other pharmaceutical companies pursuing similar products. Many endocrinologists believe the arrival of weekly insulin therapy could become one of the most transformative changes in diabetes management since the introduction of modern long-acting insulin analogs.
Key Points Summary
FDA approval date: March 26, 2026.
Drug name: Awiqli® (insulin icodec-abae).
Manufacturer: Novo Nordisk.
Indication: Adults with Type 2 Diabetes.
Major breakthrough: First once-weekly basal insulin approved in the United States.
Clinical evidence: Supported by the ONWARDS Phase 3a program involving roughly 2,680 participants.
Benefit: Reduces injections from daily to weekly.
Recent medical coverage: Multiple expert reviews and journal reports published in April–May 2026 highlighted the significance of the approval.
Current limitation: Not approved in the U.S. for Type 1 Diabetes due to hypoglycemia concerns.
advertisement
Frequently Asked Questions [FAQ]
What is Awiqli?
Awiqli (insulin icodec-abae) is a long-acting basal insulin designed to be injected once every week for adults with Type 2 Diabetes.
When did the FDA approve Awiqli?
The FDA approved Awiqli on March 26, 2026.
Why is Awiqli important?
It is the first FDA-approved once-weekly basal insulin, significantly reducing the number of injections required for diabetes management.
How often is Awiqli taken?
Awiqli is injected once every seven days using a prefilled FlexTouch pen.
What clinical trials supported approval?
The ONWARDS Phase 3a clinical trial program, involving approximately 2,680 adults with Type 2 Diabetes, provided the primary evidence supporting FDA approval.
Is Awiqli approved for Type 1 Diabetes?
No. The current FDA approval is limited to adults with Type 2 Diabetes. Concerns about hypoglycemia risk in Type 1 Diabetes patients remain under evaluation.
What are the potential benefits of once-weekly insulin?
Potential benefits include improved adherence, reduced injection burden, increased convenience, and sustained blood sugar control throughout the week.
Sources
Disclaimer:
What is mentioned in this article is for advice and is not a substitute for consulting a doctor
Thank you !
